{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:02:13Z","timestamp":1786118533858,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1097\/01.shk.0000235091.38174.8d","type":"journal-article","created":{"date-parts":[[2006,11,18]],"date-time":"2006-11-18T02:44:51Z","timestamp":1163817891000},"page":"544-550","source":"Crossref","is-referenced-by-count":42,"title":["THE OCCURRENCE OF SEVERE SEPSIS AND SEPTIC SHOCK ARE RELATED TO DISTINCT PATTERNS OF CYTOKINE GENE EXPRESSION"],"prefix":"10.1097","volume":"26","author":[{"given":"Michael J.","family":"O'Dwyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun K.","family":"Mankan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Stordeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"O'Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edel","family":"Duggan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dermot P.","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"McManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210213","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/00003246-199206000-00025","article-title":"Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.","volume":"20","year":"1992","journal-title":"Crit Care Med"},{"key":"R2-3-20210213","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00003246-200107000-00002","article-title":"Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.","volume":"29","author":"Angus","year":"2001","journal-title":"Crit Care Med"},{"key":"R3-3-20210213","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nature01326","article-title":"The immunopathogenesis of sepsis.","volume":"420","author":"Cohen","year":"2002","journal-title":"Nature"},{"key":"R4-3-20210213","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0140-6736(96)06413-6","article-title":"Genetic influence on cytokine production and fatal meningococcal disease.","volume":"349","author":"Westendorp","year":"1997","journal-title":"Lancet"},{"key":"R5-3-20210213","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0140-6736(05)60606-X","article-title":"Anti-inflammatory cytokine profile and mortality in febrile patients.","volume":"351","author":"van Dissel","year":"1998","journal-title":"Lancet"},{"key":"R6-3-20210213","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nm0697-678","article-title":"Monocyte deactivation in septic patients: restoration by IFN-gamma treatment.","volume":"3","author":"Docke","year":"1997","journal-title":"Nat Med"},{"key":"R7-3-20210213","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/01.CCM.0000150958.20209.A3","article-title":"Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients.","volume":"33","author":"Pachot","year":"2005","journal-title":"Crit Care Med"},{"key":"R8-3-20210213","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0022-1759(01)00489-6","article-title":"Cytokine mRNA quantification by real-time PCR.","volume":"259","author":"Stordeur","year":"2002","journal-title":"J Immunol Methods"},{"key":"R9-3-20210213","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clim.2004.08.015","article-title":"Longitudinal study of cytokine and immune transcription factor mRNA expression in septic shock.","volume":"114","author":"Pachot","year":"2005","journal-title":"Clin Immunol"},{"key":"R10-3-20210213","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","article-title":"A new Simplified Acute Physiology Score (SAPS II) based on a European\/North American multicenter study.","volume":"270","author":"Le Gall","year":"1993","journal-title":"JAMA"},{"key":"R11-3-20210213","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine.","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"R12-3-20210213","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","article-title":"Interleukin-10 and the interleukin-10 receptor.","volume":"19","author":"Moore","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"R13-3-20210213","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.4049\/jimmunol.146.10.3444","article-title":"IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.","volume":"146","author":"Fiorentino","year":"1991","journal-title":"J Immunol"},{"key":"R14-3-20210213","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.CCM.0000104950.52577.97","article-title":"Plasma interferon-gamma and interleukin-10 concentrations in systemic meningococcal disease compared with severe systemic Gram-positive septic shock.","volume":"32","author":"Bjerre","year":"2004","journal-title":"Crit Care Med"},{"key":"R15-3-20210213","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJM199606273342603","article-title":"Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.","volume":"334","author":"Fisher","year":"1996","journal-title":"N Engl J Med"},{"key":"R16-3-20210213","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1097\/00003246-199509000-00004","article-title":"CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group.","volume":"23","author":"Dhainaut","year":"1995","journal-title":"Crit Care Med"},{"key":"R17-3-20210213","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00003246-199605000-00003","article-title":"Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.","volume":"24","author":"Reinhart","year":"1996","journal-title":"Crit Care Med"},{"key":"R18-3-20210213","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1146\/annurev.immunol.15.1.749","article-title":"Cellular responses to interferon-gamma.","volume":"15","author":"Boehm","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"R19-3-20210213","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.4049\/jimmunol.173.6.4075","article-title":"STAT4 is a critical mediator of early innate immune responses against pulmonary Klebsiella infection.","volume":"173","author":"Deng","year":"2004","journal-title":"J Immunol"},{"key":"R20-3-20210213","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9610(01)00754-1","article-title":"Severe sepsis induces deficient interferon-gamma and interleukin-12 production, but interleukin-12 therapy improves survival in peritonitis.","volume":"182","author":"Ono","year":"2001","journal-title":"Am J Surg"},{"key":"R21-3-20210213","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1128\/AAC.48.12.4513-4519.2004","article-title":"Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection.","volume":"48","author":"Pammit","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-3-20210213","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00000372-200208000-00006","article-title":"Interferon-gamma treatment induces granulomatous tissue reaction in a case of localized cutaneous leishmaniasis.","volume":"24","author":"Haas","year":"2002","journal-title":"Am J Dermatopathol"},{"key":"R23-3-20210213","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0001-706X(98)00097-7","article-title":"Immunochemotherapy with interferon-gamma and multidrug therapy for multibacillary leprosy.","volume":"72","author":"Barral-Netto","year":"1999","journal-title":"Acta Trop"},{"key":"R24-3-20210213","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(96)12273-X","article-title":"Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol.","volume":"349","author":"Condos","year":"1997","journal-title":"Lancet"},{"key":"R25-3-20210213","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/00003246-199803000-00010","article-title":"Interferon-gamma in the prevention of severe burn-related infections: a European phase III multicenter trial. The Severe Burns Study Group.","volume":"26","author":"Wasserman","year":"1998","journal-title":"Crit Care Med"},{"key":"R26-3-20210213","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0002-9610(92)90099-D","article-title":"A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients.","volume":"163","author":"Polk","year":"1992","journal-title":"Am J Surg"},{"key":"R27-3-20210213","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1097\/00003246-200207000-00015","article-title":"Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-gamma.","volume":"30","author":"Nakos","year":"2002","journal-title":"Crit Care Med"},{"key":"R28-3-20210213","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.immunol.16.1.495","article-title":"The interleukin-12\/interleukin-12-receptor system: role in normal and pathologic immune responses.","volume":"16","author":"Gately","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"R29-3-20210213","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1084\/jem.176.5.1387","article-title":"Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells.","volume":"176","author":"D'Andrea","year":"1992","journal-title":"J Exp Med"},{"key":"R30-3-20210213","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.4049\/jimmunol.158.9.4381","article-title":"In vivo production and function of IL-12 p40 homodimers.","volume":"158","author":"Heinzel","year":"1997","journal-title":"J Immunol"},{"key":"R31-3-20210213","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/eji.200425677","article-title":"IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human.","volume":"35","author":"Vanden Eijnden","year":"2005","journal-title":"Eur J Immunol"},{"key":"R32-3-20210213","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.4049\/jimmunol.151.4.1938","article-title":"IL-12 induces the production of IFN-gamma by neonatal human CD4 T cells.","volume":"151","author":"Wu","year":"1993","journal-title":"J Immunol"},{"key":"R33-3-20210213","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.4049\/jimmunol.145.11.3796","article-title":"IL-4 directs the development of Th2-like helper effectors.","volume":"145","author":"Swain","year":"1990","journal-title":"J Immunol"},{"key":"R34-3-20210213","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jama.1995.03530020090038","article-title":"Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group.","volume":"274","author":"Goldie","year":"1995","journal-title":"JAMA"},{"key":"R35-3-20210213","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00003246-199703000-00006","article-title":"Sepsis and serum cytokine concentrations.","volume":"25","author":"Damas","year":"1997","journal-title":"Crit Care Med"}],"container-title":["Shock"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00024382-200612000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:08:45Z","timestamp":1786032525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00024382-200612000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.shk.0000235091.38174.8d","relation":{},"ISSN":["1073-2322"],"issn-type":[{"value":"1073-2322","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}